Core Insights - Onco-Innovations Limited has announced that its manufacturing partner, Dalton Pharma Services, has begun process optimization and intermediate scale-up activities for its proprietary PNKP Inhibitor Technology, A83B4C63 [1] Company Developments - The current phase of work aims to refine and scale the synthesis process under non-GMP conditions as part of Onco's ongoing manufacturing development program [1] - This initiative supports future clinical material production, indicating progress in the company's development pipeline [1]